The known and unknown of SGLT2 inhibition in CKD
ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.
Video navigation menu
- The knowns and unknowns of SGLT2-i in CKD 00:40
- Mechanisms of benefit of SGLT2-i in CKD 04:42
- Reduced tubular Na+ reabsorption and tubuloglomerular feedback 05:57
- Normalisation of impaired autophagy 08:33
- Shift to a more efficient metabolic substrate 10:21
- Reduced oxidative stress 15:15
- Relative benefits of combined SGLT1/2 inhibitors 16:51
This lecture by prof. Carol Pollock was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"
Prof. Carol Pollock, MD, Nephrologist, The University of Sydney School of Medicine, Australia
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.